Article
TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
Journal of thrombosis and haemostasis : JTH - 1 Jul 2005
Morange P E, Tregouet D A, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I
Abstract excerpt
OBJECTIVES: To evaluate the association of thrombin-activatable fibrinolysis inhibitor (TAFI) gene polymorphisms with the risk of coronary heart disease (CHD) and with TAFI levels measured by a newly developed enzyme-linked immunosorbent assay (ELISA) (TAFI-1B1), shown to be a reliable method for detecting quantitative variations in circulating TAFI. PATIENTS/METHODS: Six polymorphisms (C-2599G, G-438A,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
